Search Medical Condition
Please enter condition
Please choose location from dropdown

Fussa, Japan Clinical Trials

A listing of Fussa, Japan clinical trials actively recruiting patients volunteers.

RESULTS

Found (65) clinical trials

Study of NAC of GA Therapy for Patients With BRPC

Gemcitabine plus nub-paclitaxel (GA) regimen was recently presented at an international oncology meeting and represents a new standard regimen in the treatment of metastatic pancreatic cancer. GA is one of the high response rate treatment regimen, the investigators considered as a promising treatment as neoadjuvant chemotherapy. On the other hand, ...

Phase

9.24 miles

Learn More »

A Phase II Study of M2951 in Systemic Lupus Erythematosus (SLE)

M2951 is an investigational drug under evaluation for treatment of autoimmune and inflammatory disorders. The purpose of the study is to assess the Safety and Efficacy of M2951 in Subjects with Systemic Lupus Erythematosus (SLE)

Phase

9.72 miles

Learn More »

Medtronic Evolut Transcatheter Aortic Valve Replacement in Low Risk Patients

Multi-center, international, prospective, randomized, interventional, pre-market. Subjects will be randomized on 1:1 basis to either TAVR with the Medtronic TAVR system or to SAVR. Patients will be seen at pre and post-procedure, discharge, 30 days, 6 months, 1 year, 18 months, and annually through 10 years. The expanded use addendum ...

Phase N/A

9.72 miles

Learn More »

A Study to Assess Safety and Efficacy of Avalglucosidase Alfa Administered Every Other Week in Pediatric Patients With Infantile-onset Pompe Disease Previously Treated With Alglucosidase Alfa

The duration of the study per patient will be up to 3 years that will consist of a 14-day screening period, that may be extended to up to 4 weeks in pre-specified situations, a 25-week treatment period, a 120-week extension period, and a 4-week post-treatment observation period.

Phase

9.72 miles

Learn More »

Safety and Efficacy of Pembrolizumab (MK-3475) in Combination With TS-1+Cisplatin or TS-1+Oxaliplatin as First Line Chemotherapy in Gastric Cancer (MK-3475-659/KEYNOTE-659)

Approximately 45 participants will be assigned first to pembrolizumab + oxaliplatin + TS-1 combination therapy (Cohort 1), and then 45 participants will be assigned to pembrolizumab + cisplatin + TS-1 combination therapy (Cohort 2).

Phase

9.83 miles

Learn More »